Merck, GE team for AD treatment research

Editorial Staff | | Health Imaging | Molecular Imaging

Merck and GE Healthcare have made a clinical study collaboration, license and supply agreement for the PET imaging agent [18F]Flutemetamol to support Merck’s development of MK-8931, the company’s lead investigational candidate for Alzheimer’s disease (AD).

MK-8931 is an oral beta amyloid precursor protein site cleaving enzyme inhibitor designed to modify disease progression and improve symptom control, according to a press release from Merck and GE.

Under the agreement, GE will supply [18F]Flutemetamol for patient selection during clinical trials and to evaluate the MK-8931 agent. A joint Merck and GE Imaging Advisory Committee will oversee the planned imaging studies.

Editorial Staff

Related Content

Experts update AUC for amyloid, tau PET imaging for first time in more than a decade
Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.